Publication

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

CREDENCE Trial Investigators, Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P. -L., De Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., Zhang, H., Zinman, B., Meininger, G., Brenner, B. M. & Mahaffey, K. W., 13-Jun-2019, In : New England Journal of Medicine. 380, 24, p. 2295-2306 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

CREDENCE Trial Investigators, Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., ... Mahaffey, K. W. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380(24), 2295-2306. https://doi.org/10.1056/NEJMoa1811744

Author

CREDENCE Trial Investigators ; Perkovic, V. ; Jardine, M. J. ; Neal, B. ; Bompoint, S. ; Heerspink, H. J. L. ; Charytan, D. M. ; Edwards, R. ; Agarwal, R. ; Bakris, G. ; Bull, S. ; Cannon, C. P. ; Capuano, G. ; Chu, P. -L. ; De Zeeuw, D. ; Greene, T. ; Levin, A. ; Pollock, C. ; Wheeler, D. C. ; Yavin, Y. ; Zhang, H. ; Zinman, B. ; Meininger, G. ; Brenner, B. M. ; Mahaffey, K. W. / Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. In: New England Journal of Medicine. 2019 ; Vol. 380, No. 24. pp. 2295-2306.

Harvard

CREDENCE Trial Investigators, Perkovic, V, Jardine, MJ, Neal, B, Bompoint, S, Heerspink, HJL, Charytan, DM, Edwards, R, Agarwal, R, Bakris, G, Bull, S, Cannon, CP, Capuano, G, Chu, P-L, De Zeeuw, D, Greene, T, Levin, A, Pollock, C, Wheeler, DC, Yavin, Y, Zhang, H, Zinman, B, Meininger, G, Brenner, BM & Mahaffey, KW 2019, 'Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy', New England Journal of Medicine, vol. 380, no. 24, pp. 2295-2306. https://doi.org/10.1056/NEJMoa1811744

Standard

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. / CREDENCE Trial Investigators; Perkovic, V.; Jardine, M. J.; Neal, B.; Bompoint, S.; Heerspink, H. J. L.; Charytan, D. M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C. P.; Capuano, G.; Chu, P. -L.; De Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D. C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B. M.; Mahaffey, K. W.

In: New England Journal of Medicine, Vol. 380, No. 24, 13.06.2019, p. 2295-2306.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

CREDENCE Trial Investigators, Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019 Jun 13;380(24):2295-2306. https://doi.org/10.1056/NEJMoa1811744


BibTeX

@article{57a2f6b8312e46b6bd21b15674e79d79,
title = "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy",
abstract = "Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. Methods In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of",
keywords = "KIDNEY-DISEASE, EMPAGLIFLOZIN",
author = "{CREDENCE Trial Investigators} and V. Perkovic and Jardine, {M. J.} and B. Neal and S. Bompoint and Heerspink, {H. J. L.} and Charytan, {D. M.} and R. Edwards and R. Agarwal and G. Bakris and S. Bull and Cannon, {C. P.} and G. Capuano and Chu, {P. -L.} and {De Zeeuw}, D. and T. Greene and A. Levin and C. Pollock and Wheeler, {D. C.} and Y. Yavin and H. Zhang and B. Zinman and G. Meininger and Brenner, {B. M.} and Mahaffey, {K. W.}",
year = "2019",
month = "6",
day = "13",
doi = "10.1056/NEJMoa1811744",
language = "English",
volume = "380",
pages = "2295--2306",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "MASSACHUSETTS MEDICAL SOC",
number = "24",

}

RIS

TY - JOUR

T1 - Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

AU - CREDENCE Trial Investigators

AU - Perkovic, V.

AU - Jardine, M. J.

AU - Neal, B.

AU - Bompoint, S.

AU - Heerspink, H. J. L.

AU - Charytan, D. M.

AU - Edwards, R.

AU - Agarwal, R.

AU - Bakris, G.

AU - Bull, S.

AU - Cannon, C. P.

AU - Capuano, G.

AU - Chu, P. -L.

AU - De Zeeuw, D.

AU - Greene, T.

AU - Levin, A.

AU - Pollock, C.

AU - Wheeler, D. C.

AU - Yavin, Y.

AU - Zhang, H.

AU - Zinman, B.

AU - Meininger, G.

AU - Brenner, B. M.

AU - Mahaffey, K. W.

PY - 2019/6/13

Y1 - 2019/6/13

N2 - Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. Methods In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of

AB - Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. Methods In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of

KW - KIDNEY-DISEASE

KW - EMPAGLIFLOZIN

U2 - 10.1056/NEJMoa1811744

DO - 10.1056/NEJMoa1811744

M3 - Article

VL - 380

SP - 2295

EP - 2306

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 24

ER -

ID: 93747596